View source for 18271366. MONOVALENT AND MULTIVALENT VACCINES FOR PREVENTION AND TREATMENT OF DISEASE simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)

=MONOVALENT AND MULTIVALENT VACCINES FOR PREVENTION AND TREATMENT OF DISEASE=


==Organization Name==

[[:Category:THE REGENTS OF THE UNIVERSITY OF CALIFORNIA|THE REGENTS OF THE UNIVERSITY OF CALIFORNIA]]


[[Category:THE REGENTS OF THE UNIVERSITY OF CALIFORNIA]]

==Inventor(s)==

[[:Category:Nicole F. Steinmetz of La Jolla CA (US)|Nicole F. Steinmetz of La Jolla CA (US)]][[Category:Nicole F. Steinmetz of La Jolla CA (US)]]

[[:Category:Oscar A. Ortega-rivera of La Jolla CA (US)|Oscar A. Ortega-rivera of La Jolla CA (US)]][[Category:Oscar A. Ortega-rivera of La Jolla CA (US)]]

[[:Category:Jonathan K. Pokorski of La Jolla CA (US)|Jonathan K. Pokorski of La Jolla CA (US)]][[Category:Jonathan K. Pokorski of La Jolla CA (US)]]

==MONOVALENT AND MULTIVALENT VACCINES FOR PREVENTION AND TREATMENT OF DISEASE - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18271366 titled 'MONOVALENT AND MULTIVALENT VACCINES FOR PREVENTION AND TREATMENT OF DISEASE

==Simplified Explanation==

The patent application relates to compositions, methods, and uses involving virus or virus-like particles containing epitopes of pathogens causing diseases or cholesterol checkpoint proteins.

* The invention involves compositions comprising virus or virus-like particles with epitopes of disease-causing pathogens or cholesterol checkpoint proteins.
* Methods are provided for utilizing these compositions for various purposes, such as diagnostics, vaccines, or therapeutic treatments.

== Potential Applications ==
The technology could be applied in:
* Development of diagnostic tools for detecting specific pathogens.
* Creation of vaccines targeting disease-causing pathogens.
* Design of therapeutic treatments for diseases related to cholesterol checkpoint proteins.

== Problems Solved ==
This technology addresses the following issues:
* Efficient detection and identification of pathogens causing diseases.
* Development of targeted vaccines for specific pathogens.
* Treatment options for diseases involving cholesterol checkpoint proteins.

== Benefits ==
The technology offers the following benefits:
* Enhanced accuracy in diagnosing diseases.
* Targeted and effective vaccines against specific pathogens.
* Potential for personalized therapeutic treatments based on individual cholesterol checkpoint protein profiles.

== Potential Commercial Applications ==
The technology could be commercially applied in:
* Pharmaceutical companies for vaccine development.
* Diagnostic companies for creating pathogen detection kits.
* Biotechnology firms for therapeutic drug development targeting cholesterol checkpoint proteins.

== Possible Prior Art ==
One possible prior art could be the use of virus-like particles in vaccine development or diagnostics. Research on epitope-based vaccines may also be relevant in this context.

=== Unanswered Questions ===

=== How does this technology compare to existing diagnostic methods for pathogen detection? ===
This technology offers the potential for more targeted and accurate pathogen detection, but its sensitivity and specificity compared to traditional methods need to be evaluated through further studies.

=== What are the potential challenges in commercializing this technology for therapeutic applications? ===
Commercializing therapeutic treatments based on cholesterol checkpoint proteins may face regulatory hurdles and require extensive clinical trials to demonstrate safety and efficacy.


==Original Abstract Submitted==

Provided are compositions, methods and uses relating to one or more virus or virus-like particle(s), each of which comprises at least one epitope(s) of a pathogen causing the disease or one or more of the cholesterol checkpoint protein(s).



[[Category:A61K39/215]]
[[Category:A61K39/00]]
[[Category:A61K39/385]]
[[Category:A61P31/14]]